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mbracing
iversity in Remodeling
Step in Therapeutic
ecision Making in Heart Failure?*
ellaprada Chandrashekhar, MD
inneapolis, Minnesota
The universe is full of magical things waiting for our wits to
grow sharper.
Eden Phillpotts (1)
eart failure (HF) is characterized by adverse cardiac
tructural changes, including myocellular hypertrophy, in-
erstitial disruption, and a reduction in number of cardio-
yocytes (2–4). These changes, collectively called cardiac
emodeling, cause chamber enlargement/dysfunction, me-
iate progression, and predict adverse prognosis in patients
ith HF. Traditionally, 2 major patterns have been de-
cribed: concentric remodeling, related to pressure overload
PO), in which increased mass is associated with normal
hamber volume, and eccentric remodeling, related to vol-
me overload (VO), in which increased mass is associated
ith an increased chamber volume. Very often a mixed
icture is present, and concentric remodeling might change
o an eccentric one with worsening HF.
See page 811
Despite controversy about these terms (5), they continue
o have utility to practicing clinicians for describing mor-
hology, identifying possible etiology, and predicting prog-
osis. However, clinicians have been less concerned about
ifferences at a cellular level and more importantly, have not
een a need to adopt different treatment strategies based on
emodeling patterns. Thus, vasodilator therapy, so effective
n ischemic and dilated cardiomyopathy, has been tried in
atients with VO remodeling after aortic regurgitation (AR)
nd mitral regurgitation (MR) with controversial and
ostly negative results (6). The report by Ryan et al. (7) in
his issue of the Journal helps to place some cellular level
ackground to clinical therapeutic strategies. This group
Editorials published in the Journal of the American College of Cardiology reflect the
iews of the authors and do not necessarily represent the views of the JACC or the
merican College of Cardiology.t
From the Division of Cardiology, VA Medical Center and University of Minne-
ota, Minneapolis, Minnesota.xtends their previous work, showing inefficacy of
ngiotensin-converting enzyme inhibition (ACE-I) in VO
emodeling in yet another condition (aortocaval fistula
ACF]). Their study had 2 important findings. First, early
eft ventricular (LV) dilatation after an ACF is caused by a
apid loss of interstitial collagen (caused by a bradykinin
BK]–matrix metalloproteinase [MMP] mediated degrada-
ion), without cardiomyocyte remodeling. A BK2 receptor
ntagonist (Hoe 140) largely attenuated this early LV
ilatation. Second, ACE-I did not attenuate LV dilatation
fter ACF. This study has implications for therapy in VO
eart failure. A brief overview of the pathogenesis of VO
ersus PO remodeling and some related issues might help to
ut this study into a clinical perspective.
omponents of Remodeling:
yocyte Versus Interstitium
The true mystery of the world is the visible,
not the invisible.
Oscar Wilde (8)
yan et al. (7) found that LV dilatation in VO was caused
y connective tissue dissolution and not myocyte remodel-
ng. Does it matter what components make up the remod-
led heart? All forms of remodeling respond with some
hange in cell volume, number, and collagen. The degree of
hange in cardiomyocyte versus the interstitium is, however,
ynamic and varies with the stimulus (PO vs. VO) as well as
ts duration. In general, volume overload, with its diastolic
all stress, is initially geared to accommodating a larger
olume; it accomplishes this through a lack of increase (or
eduction) of interstitial collagen rather than a lengthening
f the myocyte. Subsequently, the myocyte starts to hyper-
rophy. These models often do not show contractile dys-
unction even with significant remodeling (9) until very late.
his is in agreement with clinical experience in MR and
R. Pressure overload, with high systolic wall stress, is
nitially geared to accommodate high pressure; it accom-
lishes that with cellular hypertrophy and a somewhat later
ncrease in interstitial fibrosis. Significant fibrosis often
arks the onset of decompensation (transition from hyper-
rophy to failure) (9). In both VO and PO, length-to-width
atio is initially preserved. Clinical decompensation is often
arked by a further increase in length without a propor-
ionate increase in width (3). Many of the clinical heart
ailure syndromes have a mixed picture of cellular hypertro-
hy and increased fibrosis.
Is one component more important than the other?
lthough both of these elements are changed in most heart
ailure syndromes, one can change without the other (10).
here is emerging doubt regarding whether cardiomyocyte
emodeling is the most important defect in the remodeling
eart. First, all cardiomyocyte remodeling is not bad and we
an now differentiate and manipulate pathways to induce
ood vs. bad cardiomyocyte hypertrophy (11,12). Second,
here is growing evidence, albeit controversial, that the
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February 20, 2007:822–5 Editorial Commentemodeled cardiomyocyte does not necessarily contribute to
hole-heart dysfunction (13,14). Finally, transgenic studies
ave shown that florid heart failure can coexist at a time
hen there is dissociation between cardiomyocyte hypertro-
hy and interstitial tissue changes; hearts can manifest
brosis and contractile dysfunction without hypertrophy
10), although some forms of obvious hypertrophy can avoid
eart failure (15). Similarly, one can selectively modulate
ontractility and hypertrophy independent of each other
12,16), and inhibiting hypertrophy is not essential to
mproving function in the failing heart.
Fibrosis seems to be detrimental in ventricular remodel-
ng of nearly all etiologies, but this conviction may change
ith further incisive investigations. Myocardial injury gen-
rates fibrosis both at the site of and remote from the initial
njury (17). A dynamic interaction between extracellular
atrix formation, qualitative alterations (e.g., type I/type
II), and degradation is an ongoing element of ventricular
emodeling. Significant ventricular dilatation can occur even
hen collagen synthesis exceeds degradation, related to the
ype of collagen laid down (e.g., the more elastic type III),
hange in collagen cross-linking, or alterations in interac-
ion with adhesion molecules or cardiomyocytes (9). Not
urprisingly, decompensation is associated with increasing
brosis. Conditions with significant remodeling that have
redominant fibrosis (and little cardiomyocyte hypertrophy)
espond to modulation of the fibrosis (18). Finally, the
enefit seen with MMP inhibition strengthens the role of
brosis in all forms of heart failure. The data from Ryan
t al. (7), from MMP knock out studies, and from inhibiting
ndothelin 1 suggest that any deviation from normal colla-
en, either less or more, might have pathogenetic implica-
ions. It thus seems that the proportion of changes in cell
olume, number, and collagen might also affect strategies to
ttenuate remodeling.
hy Is ACE-I Less Effective in VO Remodeling?
We shall never cease from exploration and the end of all our
exploring will be to arrive where we started and know the place
for the first time.
T. S. Eliot (8)
yan et al. (7) did not find a benefit of ACE-I in ACF. This
aises a question about where ACE inhibitors act and
hether there are any predictors that separate VO and PO
n terms of therapy. A complete renin–angiotensin system
xists in various cells of the heart (15). Locally produced
ngiotensin II (Ang-II) modulates cardiomyocytes and fi-
rous tissue at the site of myocardial injury as well as remote
rom it in both VO and PO. One of the main effects of
ng-II is augmenting fibrosis at the site of injury. These
esponses are transduced by AT-1 receptors, which are
ainly expressed in cardiac fibroblasts. It might even be that
he bulk of the Ang-II action is on modulating and
culpting the interstitium, maybe even more than myocyte
emodeling. The ACE-I reduces cardiomyocyte remodeling ond cardiac fibrosis in a number of cardiac injury models. So
hy did ACE-I therapy not benefit VO HF? There could
e multiple reasons, in addition to the one postulated by
yan et al. (7). A comparison of the degree of myocyte and
hamber remodeling, collagen volume, and known effect of
CE-I is instructive. As seen in Figure 1, beneficial effects
f ACE-I seem to be little correlated with myocyte size,
yocyte function, and LV chamber size. However, ACE-I
as consistently benefited conditions in which fibrosis is a
trong component of remodeling, although ACE inhibitors
ave had little success in conditions in which fibrosis is not
rominent. Consistent with the AT-1 receptor distribution
ata, one could thus postulate that ACE-I benefits are more
redicated on there being a strong fibrous tissue response
nd less so on cardiomyocyte remodeling. Lacking signifi-
ant fibrosis, ACE-I possibly had no major target to
odulate in VO remodeling of ACF or MR. This construct
eeds further evaluation. This postulate in no way, however,
egates the voluminous data about Ang II and ACE-I on
yocyte hypertrophy, apoptosis, and other phenomena, but
ust establishes a preliminary correlation with the best
redictor of ACE-I response.
CE-I, BK, and MMP in the Remodeling Heart
Two paradoxes are better than one; they may even
suggest a solution.
Edward Teller (19)
inally, Ryan et al. (7) also showed that ventricular remodeling
n the VO heart was mediated by the BK–MMP axis, and this
as postulated to be the reason that ACE-I was ineffective
espite the fact that the renin–angiotensin axis is very active in
he VO heart. Once again it is instructive to place BK in the
ontext of all forms of ventricular remodeling.
Bradykinin, because of its potent hypotrophic effects on
he myocyte and interstitium via BK2 receptors, can
trongly attenuate ventricular remodeling (20,21); ACE has
great proclivity to inactivate bradykinin, and ACE-I
ncreases tissue bradykinin levels. Not surprisingly, a signif-
cant amount of the ACE-I effectiveness is contingent on
K increase (20). Ryan et al. (7) suggest that a significant
mount of the ACE-I ineffectiveness in VO may also be
ontingent on BK increase. Unfortunately, they do not have
ata to show that long-term BK2 inhibition alone, or better
et given with ACE-I, would improve remodeling. This
eaves the story incomplete. Second, although ACE-I did
ot benefit remodeling in ACF, it did not significantly
orsen it either (even with the additional possibility that
CE-I concomitantly could also have increased another
otent antifibrotic compound N-acetyl-seryl-aspartyl-lysyl-
roline [22]). Presumably, if BK is responsible for adverse
emodeling (by fibrous tissue dissolution, etc.), more BK
fter ACE-I theoretically should have made remodeling
orse. This did not happen. Either the additional excess of
K is not needed for further remodeling (ceiling effect?) or
ther mechanisms are also at play.
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Editorial Comment February 20, 2007:822–5Alternatively, because BK (either spontaneously or after
CE-I) is antiproliferative and antifibrotic, BK2 benefits
and thus ACE-I benefits) might depend on the degree of
nderlying fibrosis or myocyte hypertrophy. Although there
re few comprehensive data, BK seems to have a somewhat
reater effect on fibrous tissue compared with cardiomyo-
ytes (18). It is also interesting that the AT2 receptors
which have potent antigrowth activities) seem to predom-
nantly modulate fibrosis (via a BK2 pathway) and not
yocyte hypertrophy after Ang II infusion or after myocar-
ial infarction (23). Thus, one could logically postulate that
he BK2 effect (or ACE-I–induced BK effect) might be
ost prominent and beneficial in conditions in which there
s significant fibrous tissue proliferation, such as after
yocardial infarction, in aortic banding, in renovascular
ypertension, or in diabetic cardiomyopathy, in which
ttenuation of fibrous tissue might be most important. In
O, with little proliferation or even a net loss of fibrous
Figure 1 Relationship Between Cardiomyocyte and Whole Hear
Representative myocyte and left ventricular remodeling data are derived from mult
data shown is percent change compared with sham-operated animals. All non-sha
expected variability in the available data. Some studies show significantly reduced
Fistula), whereas others show minimal change depending on the time point. A few
angiotensin-converting enzyme inhibition (ACE-I). Pacing-induced heart failure data
classification of volume overload versus pressure overload remodeling. Response
AR  aortic regurgitation; HT  hypertension; LVEDD  left ventricular end-diastol
tion; MR  mitral regurgitation.issue, BK augmentation might have a lesser effect. This fits rith the known difference in the magnitude of benefits of
CE-I in PO versus VO remodeling (Fig. 1). The avail-
bility of serum markers for interstitial collagen turnover
nd newer imaging techniques might help us to clarify
hether fibrous tissue quantitation will allow us to identify
esponders versus nonresponders to ACE-I in various forms
f ventricular remodeling.
Are there other explanations for the ACE-I–BK–MMP
heory in ACF? There remains the possibility that Hoe 140
ncreased blood pressure, and this might have reduced the
threatened blood pressure” response with ACF (24). Be-
ause vasodilation after ACF has a prominent role in salt
nd water retention and thus diastolic wall stress, any
ressor agent could have reduced the stimulus to remodel
nd thus falsely show benefit. The investigators rightly used
ther pressor controls. For a similar degree of pressor
esponse, Ang-II increased collagen volume (less than with
oe 140), but caused myocyte hypertrophy while reducing
odeling, Interstitial Fibrosis, and Effect of ACE-I
blished reports. All studies had age-matched sham-operated controls, and
al groups showed significant remodeling and chamber dilatation. There is an
s tissue volume in MR animals, similar to that seen in aortocaval fistula (A-C
ng studies, depending on the protocol used, did not find as much benefit with
t shown because that syndrome is rather unique and does not fit into the usual
-I is shown as a qualitative depiction of the experience from multiple reports.
ension; LVESD  left ventricular end-systolic dimension; MI  myocardial infarc-t Rem
iple pu
m anim
fibrou
bandi
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ic dimemodeling. This lends credence to the collagen dissolution
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February 20, 2007:822–5 Editorial Commentheory, but also suggests that interventions inducing con-
rolled myocyte hypertrophy might also be beneficial (re-
uced wall stress theory). Second, even subpressor doses of
CE-I can directly reduce MMP generation and influence
emodeling (25); effects on MMP generation via BK2 might
e attenuated by those directly on MMP itself. Thus,
CE-I did not benefit or worsen the situation in ACF. The
MP level and activity in the chronic ACE-I group might
ave been instructive. Finally, endothelin is increased in
CF and has a similar effect on interstitial dissolution via
ast cells and MMP. An endothelin antagonist might have
enefits similar to those of Hoe 140. This would be an
nteresting area to explore (26).
linical Perspective
ow do these findings apply to everyday practice? All of the
ajor changes in this study by Ryan et al. (7) happened
ight after the acute insult, and this is far different from
hen clinicians see patients; thus, timing of intervention
ight be an issue. If the BK–MMP axis is the culprit, there
ight be a lively debate regarding inhibiting MMP itself.
he MMP inhibitors have had a long and costly develop-
ent and are likely to get better. On the other hand, mast
ell stabilizers (which reduce BK and MMP) are easier to
se. This will remain an active area of research. The
nhibition of ACE has not been clinically successful in
reventing progression in VO caused by AR or MR, and the
esults of this study are unlikely to affect current practice.
ecause late-stage VO- or PO-mediated heart failure (the
tage at which we see many patients clinically) seems to have
any more similarities in cardiac structure, it seems prema-
ure to exclude a role for ACE-I in the clearly dilated,
ate-stage failing heart (e.g., nonsurgical candidates). Fi-
ally, we are still not at a point at which all volume overload
hould be treated similarly, and there are animal data
howing that ACE-I is effective in AR (unlike MR and
CF). Interestingly, AR is associated with somewhat more
brosis than MR or ACF; if the ACE-I fibrosis theory is
roven correct, this might explain the benefits of ACE-I in
nimal studies of AR. Clinical studies have remained
ontroversial. Noninvasive measures of various components
f remodeling (27) might refine our ability to modulate
herapy in the failing heart.
eprint requests and correspondence: Dr. Yellaprada Chan-
rashekhar, Division of Cardiology 111c, VA Medical Center/
niversity of Minnesota, One Veterans Drive, Minneapolis,
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